Europe Will Not Call This Ring a Wellness Gadget

The Preorder Page Went Up on 16 July

On 16 July 2026, Tom Moss put a $399 ring on sale in the United States, and in doing so he made a decision about legal categories that will not survive the trip to Europe. Moss, whose track record runs through Skydio, Razer and Nextbit, is the chief executive of Vital Signals, a startup roughly three years old. The product is the Signal Ring. Preorders opened that day. It ships in October 2026. There is no euro price and no sterling price, because no EU or UK launch has been announced.

The pitch is specific. The ring is cuffless and requires no calibration, and Vital Signals presents that as its differentiator against the smart rings already on wrists and fingers, Oura among them. It outputs actual systolic and diastolic numbers. That last detail is the one that matters for everything downstream, because the Apple Watch, the most familiar comparison point, provides alerts rather than numeric readings. Numbers and alerts are not the same product, and regulators do not read them the same way.

The consumer model has no clearance from the United States Food and Drug Administration. It is launching in the US as a wellness device. Vital Signals has a medical-grade version in its plans, and the trial results behind that version are unpublished. None of this is a failure on the company's part. It is a routine and legitimate route to market in the United States, and plenty of well-run companies take it. The question this piece asks is narrower: what happens to that routing when the product reaches a jurisdiction that draws the line somewhere else.

Wellness Is a Category, and It Has a Border

The word "wellness" is not a description of a product in the United States, it is a regulatory carve-out, and carve-outs are drawn by the regulator that made them. In the US, the wellness category is the lane that lets a device reach consumers without going through FDA clearance. Vital Signals is using it as designed. The Food and Drug Administration has, separately and explicitly, warned against unauthorised blood-pressure wearables, which tells you the agency is watching the lane rather than ignoring it.

Under the EU Medical Device Regulation, the carve-out is far narrower, and the mechanism that decides where a product lands is intended purpose. Not the shelf it sits on. Not the word on the packaging. What the manufacturer says the device is for. A device that outputs systolic and diastolic values, aimed at people who are concerned about hypertension risk, is making a monitoring claim, and a monitoring claim pulls a product toward medical-device status, toward CE marking, and toward a notified body that will want to see evidence.

So the question of whether the Signal Ring reaches Europe is not a shipping-schedule question. It is a classification question. Owners who read tech coverage get trained to watch for launch dates and regional pricing, and those are the wrong signals here. The signal to watch is what Vital Signals states its intended purpose to be when and if it files for Europe, because that sentence, not the launch calendar, decides which regime the product enters and how long that takes.

What the Company Says, and What Bloomberg Found

There are two accounts of how this device performs, they come from different parties, and an owner should hold them apart rather than average them. Vital Signals claims, as relayed by 9to5Mac, that clinical trials show accurate readings across thousands of participants. That is the company's claim about its own product. It is reported here as a claim, attributed to the company, and this desk is not in a position to verify it and does not attempt to.

Bloomberg conducted its own hands-on testing of the ring and encountered accuracy discrepancies. Vital Signals attributed those discrepancies to how the ring was fitted. That exchange is reported here neutrally, as what each party said. This desk did not receive Bloomberg's original reporting directly, and the testing finding reached us through subsequent coverage, which is a sourcing detail worth stating plainly rather than smoothing over.

What follows from this is procedural, not clinical. This journal does not assess whether the Signal Ring is accurate, and no reader should take anything here as guidance about the device's performance. The relevant point is structural: a company claim and an independent test have produced different pictures, the trial results for the medical-grade version are unpublished, and under the European regime it is not the press and not the buyer who resolves that. It is a notified body, working from evidence the manufacturer submits, against an intended purpose the manufacturer states.

The Purchase Order Nobody Reads Twice

An EU or UK employer who buys these rings into a corporate wellness or occupational-health programme takes on two distinct exposures in a single purchase, and the purchase order will not mention either. Picture the moment concretely. An operations lead is building next year's staff benefits package, the ring reviews well, the price is legible, and rings go on the list next to the standing desks and the gym subsidy. Nothing about that moment feels like a regulatory decision. That is exactly the problem with it.

The first exposure is procurement. The employer has bought a measuring device that has not been validated for that purpose under the European regime, and has put it into a programme that treats it as fit for use. The second exposure is data protection, and it is the heavier one. Blood-pressure readings are health data. Health data is special-category data under Article 9 of the GDPR, the most tightly restricted class the regulation defines, and processing it requires a lawful basis that the employer must be able to name.

The usual answer is that staff consented. In the employment context that answer is weak, and it is weak for a reason that has been examined at length by European regulators: the power imbalance between employer and staff undermines the freeness of the consent. An employee asked to opt into a wellness programme by the organisation that decides their pay and their promotion is not making the kind of unpressured choice the regulation has in mind. Buying a gadget for staff creates a procurement exposure and an Article 9 exposure at the same time, quietly, in a line item that reads like a perk.

Two Questions Before Any Wearable Enters a Staff Programme

Before any wearable goes into a staff programme, an owner needs answers to two questions, and the second one is the one that stops most programmes. The first: what is the manufacturer's stated intended purpose? Not the marketing copy, not the review headlines, the intended purpose as the manufacturer states it, because that is the sentence a European regulator will read and it is the sentence that determines what the manufacturer has actually undertaken to deliver.

The second: what is your Article 9 lawful basis for processing the health data this device generates? Someone in the organisation must be able to answer that in a sentence, and name it. If the answer is that people opted in, that is not yet an answer, for the reason set out above. If nobody can answer the second question at all, the programme is not ready, and the correct action is to hold it rather than to pilot it and see.

None of this is a verdict on Vital Signals, which has done nothing wrong by shipping into a US category that exists and that it is entitled to use. The point is that the category does not cross the Atlantic with the product. American regulatory routing is not portable, and a device that is a wellness gadget in one jurisdiction can be an unclassified measuring instrument in another. For a European owner, the ring is not a purchasing decision that happens to have a compliance footnote. The compliance question is the decision.

Read next: 570 Windows Patches in One Day, Two Already Exploited  |  Rotate Every Secret Grok Build Ever Saw